Table 1.
Patient baseline characteristics in the study group and the control group
| Patient characteristics | Study group (%) | Control group (%) | P-value* | |
|---|---|---|---|---|
| 1 | 2 | |||
| Number | 87 (26.1) | 246 (73.9) | ||
| Sex | 0.972 | 0.960 | ||
| Male | 55 (63.2) | 155 (63) | ||
| Female | 32 (36.8) | 91 (37) | ||
| Age (years) | ||||
| Median (range) | 52 (19–83) | 51 (25–77) | 0.998 | 0.718 |
| ≤60 | 65 (73.9) | 181 (73.6) | ||
| >60 | 23 (26.1) | 65 (26.4) | ||
| Primary tumor | 0.299 | 0.661 | ||
| Colon | 53 (60.9) | 165 (67.1) | ||
| Rectum | 34 (39.1) | 81 (32.9) | ||
| Pathological type | ||||
| Adenocarcinoma | 82 | |||
| Others | 5 | |||
| Chemotherapy regimen | <0.001 | 0.482 | ||
| Oxaliplatin-based | 42 (48.3) | 202 (82.1) | ||
| Irinotecan-based | 43 (49.4) | 37 (15.0) | ||
| Fluorouracil alone | 2 (2.3) | 6 (2.4) | ||
| Other type | 1 (0.5) | |||
Note:
*
1 refers to the P-value of the balance test and 2 refers to the P-value of the elements to PFS.
Abbreviation: PFS, progression-free survival.